US20150181924A1 - Cannabidiol liquid composition for smoking - Google Patents
Cannabidiol liquid composition for smoking Download PDFInfo
- Publication number
- US20150181924A1 US20150181924A1 US14/528,051 US201414528051A US2015181924A1 US 20150181924 A1 US20150181924 A1 US 20150181924A1 US 201414528051 A US201414528051 A US 201414528051A US 2015181924 A1 US2015181924 A1 US 2015181924A1
- Authority
- US
- United States
- Prior art keywords
- composition
- cannabidiol
- smoke
- amount
- flavor enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 94
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 93
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 93
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 93
- 230000000391 smoking effect Effects 0.000 title abstract description 32
- 239000007788 liquid Substances 0.000 title abstract description 13
- 239000003571 electronic cigarette Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 32
- 235000019264 food flavour enhancer Nutrition 0.000 claims description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 25
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 24
- 239000003995 emulsifying agent Substances 0.000 claims description 20
- 239000010460 hemp oil Substances 0.000 claims description 20
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 16
- 235000013311 vegetables Nutrition 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 8
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 6
- 244000144730 Amygdalus persica Species 0.000 claims description 6
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 6
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 6
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 6
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 6
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 6
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 6
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 6
- 235000020224 almond Nutrition 0.000 claims description 6
- 240000009088 Fragaria x ananassa Species 0.000 claims description 5
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 4
- 244000298697 Actinidia deliciosa Species 0.000 claims description 4
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 244000099147 Ananas comosus Species 0.000 claims description 3
- 235000007119 Ananas comosus Nutrition 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 235000004936 Bromus mango Nutrition 0.000 claims description 3
- 240000000712 Casimiroa edulis Species 0.000 claims description 3
- 235000003936 Casimiroa edulis Nutrition 0.000 claims description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 3
- 244000241235 Citrullus lanatus Species 0.000 claims description 3
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- 244000060011 Cocos nucifera Species 0.000 claims description 3
- 235000006481 Colocasia esculenta Nutrition 0.000 claims description 3
- 244000205754 Colocasia esculenta Species 0.000 claims description 3
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 claims description 3
- 240000002495 Cucumis melo var. inodorus Species 0.000 claims description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims description 3
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 3
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 3
- 240000005385 Jasminum sambac Species 0.000 claims description 3
- 240000007049 Juglans regia Species 0.000 claims description 3
- 235000009496 Juglans regia Nutrition 0.000 claims description 3
- 244000108452 Litchi chinensis Species 0.000 claims description 3
- 241000220225 Malus Species 0.000 claims description 3
- 235000011430 Malus pumila Nutrition 0.000 claims description 3
- 235000015103 Malus silvestris Nutrition 0.000 claims description 3
- 235000014826 Mangifera indica Nutrition 0.000 claims description 3
- 240000007228 Mangifera indica Species 0.000 claims description 3
- 235000014749 Mentha crispa Nutrition 0.000 claims description 3
- 244000078639 Mentha spicata Species 0.000 claims description 3
- 240000005561 Musa balbisiana Species 0.000 claims description 3
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 3
- 235000015742 Nephelium litchi Nutrition 0.000 claims description 3
- 235000019082 Osmanthus Nutrition 0.000 claims description 3
- 241000333181 Osmanthus Species 0.000 claims description 3
- 240000004371 Panax ginseng Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 3
- 241000018646 Pinus brutia Species 0.000 claims description 3
- 235000011613 Pinus brutia Nutrition 0.000 claims description 3
- 235000014443 Pyrus communis Nutrition 0.000 claims description 3
- 240000001987 Pyrus communis Species 0.000 claims description 3
- 241000220317 Rosa Species 0.000 claims description 3
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 3
- 235000009184 Spondias indica Nutrition 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 3
- 244000263375 Vanilla tahitensis Species 0.000 claims description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 235000020279 black tea Nutrition 0.000 claims description 3
- 235000021029 blackberry Nutrition 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 235000017803 cinnamon Nutrition 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 229940010454 licorice Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000020234 walnut Nutrition 0.000 claims description 3
- 241000219112 Cucumis Species 0.000 claims 4
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 229930003827 cannabinoid Natural products 0.000 description 27
- 239000003557 cannabinoid Substances 0.000 description 27
- 229940065144 cannabinoids Drugs 0.000 description 24
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 13
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 13
- 240000004308 marijuana Species 0.000 description 13
- 229960002715 nicotine Drugs 0.000 description 13
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000779 smoke Substances 0.000 description 11
- 244000025254 Cannabis sativa Species 0.000 description 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 10
- 229960004242 dronabinol Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000004097 EU approved flavor enhancer Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 6
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 244000061176 Nicotiana tabacum Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 4
- 235000009120 camo Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960002967 nabilone Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- -1 CBD Natural products 0.000 description 2
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003863 Marijuana Abuse Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
- 201000009322 cannabis abuse Diseases 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- QHMBSVQNZZTUGM-MSOLQXFVSA-N 2-[(1s,6s)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical group OC1=CC(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-MSOLQXFVSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 240000005925 Aeschynanthus radicans Species 0.000 description 1
- 208000017167 Alcohol-Induced disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940041750 cesamet Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D1/00—Cigars; Cigarettes
- A24D1/002—Cigars; Cigarettes with additives, e.g. for flavouring
-
- A24F47/008—
Definitions
- the present invention relates to a liquid composition comprising of naturally or artificially derived cannabidiol, emulsifiers, and flavoring agents, to be smoked using a smoking device such as an electronic cigarette (e-cigarette).
- the composition may comprise cannabidiol and flavoring agents only.
- the invention provides formulations wherein cannabidiol is effectively delivered in a composition that can be used in an electronic cigarette, and the consumption of the composition by pulmonary route does not give undesirable side effects. Consumption via smoking allows pulmonary, buccal, and mucosa absorption of cannabidiol.
- Smoking is a recreational habit popular in many countries. In modern time, smoking may be accomplished through means such as cigarettes, pipes, bongs, bidis, or hookahs, etc. Most types of smoking mechanisms have disadvantages including, but not limited to, tar, second-hand smoke, and exposure to a wide range of toxins including, but not limited to, nitrogen dioxide, acrolein, carbon monoxide, lead, hydrogen cyanide, arsenic, mercury, and other harmful substances.
- Nicotine replacement therapies such as nicotine gum, are widely used, but the ritual of smoking poses another challenge. Smokers prefer the feeling of inhalation and the physical movement of the hands and lips.
- Cigarette smoke is measured in the range of pH 6.0 to 8.0.
- Delivery of a desirable substance via the pulmonary route may have an advantage of rapid absorption. While nicotine absorption via pulmonary route is detrimental to smokers, the same characteristic is desirable when a desirable substance is delivered via the pulmonary route. Consequently, smoking of marijuana plant materials is recommended for some patients. A prescription to purchase medical marijuana to smoke is required in states where such materials can be legally purchased.
- An electronic cigarette allows the user to choose a substance to be smoked, gives the user a similar physical and ritualistic experience of smoking a cigarette, while eliminating many disadvantages of smoking.
- An electronic cigarette has no tar, no second hand smoke, and no harmful compounds commonly found in tobacco based cigarettes.
- Electronic cigarettes utilize a liquid composition that vaporizes with heat application.
- Electronic cigarette liquid may contain nicotine to deliver the desired nicotine and prevent nicotine withdrawal symptoms.
- the liquid does not contain harmful substances commonly found in tobacco.
- the electronic cigarette therefore provides an alternative way to smoke and obtain nicotine, but at the same time avoid the harmful effects of inhaling tobacco smoke.
- the cannabis plant has many naturally occurring substances that are of great interest in science and medicine.
- Isolated compounds from the cannabis plant include ⁇ 9 -tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not.
- Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids isolated from the cannabis plant. Many researches confirmed the medicinal value of cannabinoids. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
- THC The IUPAC nomenclature of THC is ( ⁇ )-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol.
- CBD's IUPAC nomenclature is 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-1,3-diol).
- CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
- Cannabinoids can be isolated by extraction from cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis , and Cannabis indicia . These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
- Nabilone (racemic(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name dronabinol (( ⁇ )-(6aR,10aR)-6,6,9-trimythel-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol)). These synthetic cannabinoids are sold for food supplement purposes and investigated for medicinal purpose. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.
- THC and other cannabinoids are used to treat these conditions.
- symptoms associated with Parkinson's disease such as tremors, are also treated with cannabinoids.
- Various conditions may also be treated or alleviated by the absorption of cannabinoids and derivatives thereof.
- Conditions that may be treated or alleviated include nausea, vomiting, emesis, pain, lethargy, alcohol induced disorders, multiple sclerosis, inflammatory bowel disorders, arthritis, dermatitis, systemic lupus erythematosus, inflammation, convulsions, psychotic episodes, some cancers, peripheral neuropathic pain, diabetic neuropathy, shingles, burns, actimic keratosis, oral cavity sores and ulcers, seborrheic dermatitis, ankylosing spondylitis, Reiter syndrome, psoriatic arthritis, joint pain, chondrocalcinosis, fibromyalgia, musculoskeletal pain, polymyositis, neuropathic-postoperative complications, acute nonspecific tenosynovitis, epicondylitis, bursitis, post-traumatic osteoarthritis, juvenile rheumatoid arthritis, synovitis, pancreatitis, contact dermatitis, bullous dermatitis
- Cannabis abuse among chronic users is also seen, especially when raw cannabis plant materials are consumed by smoking. Withdrawal symptoms are observed with discontinuance of cannabis use.
- cannabis abuse is referred to as cannabis use disorder.
- cannabinoids such as CBD, may be useful in treating cannabis use disorder.
- cannabinoids Delivering cannabinoids through membranes in mammals remains a challenge. This is due to the hydrophobic nature of cannabinoids. Transdermal delivery of cannabinoids faces many challenges, and penetration enhancers are usually required for effective delivery. Pulmonary delivery has many advantages, one of which is the available surface area in the pulmonary airways.
- Cannabidiol from hemp is marketed in the United States as a dietary supplement.
- Various products containing cannabidiol have been marketed in recent years.
- Cannabidiol may be consumed by digestion or by transdermal delivery.
- a more effective method to deliver cannabidiol for fast absorption by a mammal, preferably a human being, is still sought.
- Smoking may be necessary in limited circumstances. When a person needs a certain substance to be delivered into his/her body, but the substance is only available in smoke-able form, that person's options may be limited.
- An example is the use of medical marijuana.
- Naturally occurring compounds such as cannabidiol can be found in certain parts of the marijuana plants.
- a person wishing to consume the compounds found in the marijuana plants due to health reasons and under legal conditions may be limited to smoking the plant materials.
- vaporizers are used. While eliminating some of the disadvantages of smoking by a cigarette or pipe, vaporizers are bulky, hard to set up, and inconvenient to use.
- this present invention offers a method to deliver cannabidiol via the pulmonary route while minimizing the adverse effects of smoking.
- the present invention relates to a mixture composition of cannabidiol with emulsifiers and/or flavor enhancers to form a composition to be smoked in an electronic cigarette.
- the present invention also relates to methods to make the smoke-able cannabidiol composition.
- the present invention finally relates to a smoking device containing a smoke-able cannabidiol composition.
- cannabinoid used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs ( ⁇ 9 -tetrahydrocannabinol, ⁇ 8 -tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 3-(1,1-dimethylheptyl)-6,6a7,8,10,10a-hexahydro-1-1hydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9-ol,( ⁇ )-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-1,1-dimethylheptyl, (+)-(3S,4S)-7-hydroxy- ⁇ -6-tetra
- cannabidiol refers to cannabidiol and cannabidiol derivatives. As used in this application, cannabidiol is obtained from industrial hemp extract with trace amount of THC.
- This present invention relates to a composition
- a composition comprising cannabidiol with emulsifiers and/or flavor enhancers.
- the resulting composition may be vaporized by the heat applied by an electronic cigarette.
- a mammal preferably a human, may inhale this vapor, which contains cannabidiol. Upon inhalation, the mammal may absorb the cannabidiol via pulmonary route.
- cannabidiol is naturally derived and provided as a part of hemp oil.
- Hemp oil is derived by cold-pressing of the seeds and mature stalks of the Cannabis sativa L. plant. Cold-pressed oil is then distilled to increase cannabidiol concentration.
- Impurities may be any cannabinoids that are not cannabidiol, fatty acids such as linoleic acid and ⁇ -linoleic acid, which are natural components of hemp oil, ⁇ -caryophyllene, myrcene, and ⁇ -sitosterol.
- cannabidiol may contain impurities in an amount of less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 55%, less than 50%, less than 45%, less than 40%, or less than 35%.
- cannabidiol may be artificially synthesized and is substantially free from impurities. Synthetic cannabidiol must be combined with at least one emulsifier to form a uniform liquid mixture that may be vaporized.
- the composition is a mixture of cannabidiol with an emulsifier, preferably polyethylene glycol 400 (PEG-400), but may also be propylene glycol or vegetable glycol.
- PEG-400 is highly hydrophilic. The combination of cannabidiol in hemp oil and PEG-400 gives in a uniform composition. Moreover, this composition does not separate, ensuring even distribution of cannabidiol in the composition.
- Vegetable glycol gives more smoke when the composition vaporizes during use, while propylene glycol enhances the taste of the composition during vaporization.
- the weight percentage of propylene glycol or vegetable glycol in the composition is the same as that recommended for the polyethylene glycol-400 concentration.
- a combination of different emulsifiers may be used.
- Using a combination of PEG-400 and vegetable glycol gives the composition a smoother feel, produces more smoke with each drag, while guarding against separation when the composition is left unused for extended periods.
- Cannabidiol is the main component to be delivered in this composition.
- cannabidiol concentration is present in a total amount by weight of about 0.1% to about 90%, about 0.1% to about 89%, about 0.1% to about 88%, about 0.1% to about 87%, about 0.1% to about 86%, about 0.1% to about 85%, about 0.1% to about 84%, about 0.1% to about 83%, about 0.1% to about 82%, about 0.1% to about 81%, about 0.1% to about 80%, about 0.1% to about 79%, about 0.1% to about 78%, about 0.1% to about 77%, about 0.1% to about 76%, about 0.1% to about 75%, about 0.1% to about 74%, about 0.1% to about 73%, about 0.1% to about 72%, about 0.1% to about 70.1%, about 0.1% to about 70%, about 0.1% to about 69%, about 0.1% to about 68%, about 0.1% to about 67%, about 0.1% to about 66%, about 0.1% to about 65%, about 0.1% to about 64%, about 0.1%
- cannabidiol may be present in an amount of about 1% to about 5% (wt/wt) of the composition.
- the emulsifier is present in this composition in a total amount by weight of about 10% to about 99.9%, about 10% to about 99%, about 10% to about 98%, about 10% to about 97%, about 10% to about 96%, about 10% to about 95%, about 10% to about 94%, about 10% to about 93%, about 10% to about 92%, about 10% to about 90.1%, about 10% to about 90%, about 10% to about 89%, about 10% to about 88%, about 10% to about 87%, about 10% to about 86%, about 10% to about 85%, about 10% to about 84%, about 10% to about 83%, about 10% to about 82%, about 10% to about 80.1%, about 10% to about 80%, about 10% to about 79%, about 10% to about 78%, about 10% to about 77%, about 10% to about 76%, about 10% to about 75%, about 10% to about 74%, about 10% to about 73%, about 10% to about 72%, about 10% to about 70.1%, about 10% to about 70%, about 10% to about 69%, about 10% to about 68%, about 10%
- PEG-400 comprises most of the emulsifier mass. Specifically, PEG-400 may be present by weight at between about 40% to about 80%, and vegetable glycol may be present by weight at between about 5% to about 15%. The balance of the composition may be flavor enhancer and cannabidiol.
- the composition may further comprise a flavor enhancer to substantially change the flavor of the smoke.
- the flavor enhancer is present in this composition in a total amount by weight of about 1% to about 80%, about 1% to about 79%, about 1% to about 78%, about 1% to about 77%, about 1% to about 76%, about 1% to about 75%, about 1% to about 74%, about 1% to about 73%, about 1% to about 72%, about 1% to about 70.1%, about 1% to about 70%, about 1% to about 69%, about 1% to about 68%, about 1% to about 67%, about 1% to about 66%, about 1% to about 65%, about 1% to about 64%, about 1% to about 63%, about 1% to about 62%, about 1% to about 61%, about 1% to about 60%, about 1% to about 59%, about 1% to about 58%, about 1% to about 57%, about 1% to about 56%, about 1% to about 55%, about 1% to about 54%, about
- the flavor enhancer is present in the amount by weight of about 20% to about 40% of the composition. In yet another preferred embodiment, the flavor enhancer is present in the amount by weight of about 40% to about 60% of the composition. In another embodiment, different kinds of flavor enhancer may be mixed in, such that the smoke-able composition may have multiple flavors.
- cannabidiol may be mixed with a flavor enhancer and without an emulsifier. Trace amount of water and other impurities may be present.
- cannabidiol may be supplied in less pure form, wherein the cannabidiol is in oil form with other cannabinoids and other components of hemp oil, such as linoleic acid, ⁇ -linoleic acid, ⁇ -caryophyllene, myrcene, and ⁇ -sitosterol. THC may be present in trace amounts.
- Impurities may be present in the amount of less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 35%, less than 20%, less than 15%, less than 10%, less than 5%, or less than 1%.
- Cannabidiol and a flavor enhancer may be obtained in a desired quantity.
- the two components are placed in a container and mixed using a propeller, a magnetic stirrer or a shaking mechanism.
- Magnetic stirrer is the best mixing method, as it prevents minor bubbles from forming in the mixture and affecting the smoking experience. After mixing, the composition may be used for smoking.
- cannabidiol is present in a total amount by weight of about 70% to about 95%, about 70% to about 94%, about 70% to about 93%, about 70% to about 92%, about 70% to about 91%, about 70% to about 90%, about 70% to about 89%, about 70% to about 88%, about 70% to about 87%, about 70% to about 86%, about 70% to about 85%, about 70% to about 84%, about 70% to about 83%, about 70% to about 82%, about 70% to about 80.1%, about 70% to about 80%, about 70% to about 79%, about 70% to about 78%, about 70% to about 77%, about 70% to about 76%, about 70% to about 75%, about 70% to about 74%, about 70% to about 73%, about 70% to about 72%, about 70% to about 71%.
- a flavor enhancer is present in a total amount by weight of about 5% to about 50%, 5% to about 49%, 5% to about 48%, 5% to about 47%, 5% to about 46%, 5% to about 45%, 5% to about 44%, 5% to about 43%, 5% to about 42%, 5% to about 41%, 5% to about 40%, 5% to about 39%, 5% to about 38%, 5% to about 37%, 5% to about 36%, 5% to about 35%, 5% to about 34%, 5% to about 33%, 5% to about 32%, 5% to about 31%, 5% to about 30%, about 5% to about 29%, about 5% to about 28%, about 5% to about 27%, about 5% to about 26%, about 5% to about 25%, about 5% to about 24%, about 5% to about 23%, about 5% to about 22%, about 5% to about 20.1%, about 5% to about 20%, about 5% to about 19%, about 5% to about 18%,
- Polyethylene glycol-400, propylene glycol, and vegetable glycol are widely available from industrial sellers and the marketplace.
- PEG-400 is the most effective emulsifiers, as they have strong hydrophilic capability, even though propylene glycol and vegetable glycol are also effective.
- Cannabidiol is available as an isolated extraction from the cannabis plant, namely from industrial hemp, and may be obtained on the legal market. Cannabidiol may also be obtained from synthetic sources. However, synthetic cannabidiol should only be used under strict legal requirements where legally appropriate. The synthesis of cannabidiol can be found in Navak & Salemink, TetradedronLett. 23, 253 (1982). This publication is included herein as references.
- Flavor enhancers may be chosen from the list comprising of apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any other flavor. Flavor enhancers are available for purchase commercially. Most flavor enhancers are available in oil form and mix well with cannabidiol and emulsifiers.
- Polyethylene glycol-400 (or vegetable glycol, or propylene glycol) may be combined with cannabidiol and a flavor enhancer. The resulting mixture is stirred or mixed well, either by a propeller, a magnetic stirrer, or by a shaking mechanism.
- PEG-400 is used at a concentration of about 90% (wt/wt).
- Cannabidiol derived from hemp oil is present at a concentration of about 5% (wt/wt).
- Trace amounts of water may be found in this composition.
- Cannabidiol in hemp oil dissolves well in PEG-400 and the mixture vaporizes well during smoking by an e-cigarette.
- flavor enhancers may be added into the mixture as needed. The weight percentages for flavor enhancers are given above.
- cannabidiol may contain certain impurities.
- the smoke-able cannabidiol composition may be smoked using an e-cigarette.
- the composition may be injected into an e-cigarette cartridge.
- the e-cigarette cartridge containing the smoke-able composition may be placed into an e-cigarette housing and be ready for smoking.
- the e-cigarette may be charged before the smoking of the smoke-able cannabidiol composition.
- cannabidiol Upon inhalation of the smoke from the smoke-able cannabidiol composition, cannabidiol is delivered into the pulmonary pathway and absorbed by the smoker.
- cannabidiol is provided as part of hemp oil.
- Hemp oil in the following examples contains 10% (wt/wt) of cannabidiol.
- 1 grams of hemp oil contains 0.1 gram of cannabidiol.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
Abstract
This application discloses a cannabidiol liquid composition for use in an electronic cigarette smoking device. The cannabidiol liquid composition may be used for pulmonary administration of cannabidiol for more effective absorption. A method of use for the cannabidiol liquid composition is also disclosed.
Description
- This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/898,273, filed Oct. 31, 2013.
- The present invention relates to a liquid composition comprising of naturally or artificially derived cannabidiol, emulsifiers, and flavoring agents, to be smoked using a smoking device such as an electronic cigarette (e-cigarette). The composition may comprise cannabidiol and flavoring agents only. In particular, the invention provides formulations wherein cannabidiol is effectively delivered in a composition that can be used in an electronic cigarette, and the consumption of the composition by pulmonary route does not give undesirable side effects. Consumption via smoking allows pulmonary, buccal, and mucosa absorption of cannabidiol.
- Smoking is a recreational habit popular in many countries. In modern time, smoking may be accomplished through means such as cigarettes, pipes, bongs, bidis, or hookahs, etc. Most types of smoking mechanisms have disadvantages including, but not limited to, tar, second-hand smoke, and exposure to a wide range of toxins including, but not limited to, nitrogen dioxide, acrolein, carbon monoxide, lead, hydrogen cyanide, arsenic, mercury, and other harmful substances.
- While nicotine is the primary cause of smoking addiction, many of the harmful effects from smoking are the results of carcinogens found in tobacco, or the plant material from tobacco used for smoking. Nicotine replacement therapies, such as nicotine gum, are widely used, but the ritual of smoking poses another challenge. Smokers prefer the feeling of inhalation and the physical movement of the hands and lips.
- During smoking, nicotine is carried in tar droplets, which are inhaled. The droplets, upon contact with the pulmonary membrane, are absorbed. Due to the high contact surface area in the small airways and alveoli of the pulmonary route, absorption of nicotine during smoking is more rapid. Moreover, it is suggested that nicotine is unionized in a higher alkaline environment, which facilitates rapid absorption. Cigarette smoke is measured in the range of pH 6.0 to 8.0.
- Absorption through the buccal membrane is not widely seen, unless the smoke is at a higher pH value. An alkaline environment means nicotine is unionized, which means higher absorption. Nicotine levels peak right after smoking, mainly due to the available contact surface in the lung. While nicotine and tar intake is to smokers' ultimate detriment, pulmonary delivery of desirable substances may be more effective than other methods of delivery.
- Delivery of a desirable substance via the pulmonary route may have an advantage of rapid absorption. While nicotine absorption via pulmonary route is detrimental to smokers, the same characteristic is desirable when a desirable substance is delivered via the pulmonary route. Consequently, smoking of marijuana plant materials is recommended for some patients. A prescription to purchase medical marijuana to smoke is required in states where such materials can be legally purchased.
- The recent introduction of the electronic cigarette addresses some of these legal and physical problems. An electronic cigarette allows the user to choose a substance to be smoked, gives the user a similar physical and ritualistic experience of smoking a cigarette, while eliminating many disadvantages of smoking. An electronic cigarette has no tar, no second hand smoke, and no harmful compounds commonly found in tobacco based cigarettes.
- Electronic cigarettes utilize a liquid composition that vaporizes with heat application. Electronic cigarette liquid may contain nicotine to deliver the desired nicotine and prevent nicotine withdrawal symptoms. At the same time, the liquid does not contain harmful substances commonly found in tobacco. The electronic cigarette therefore provides an alternative way to smoke and obtain nicotine, but at the same time avoid the harmful effects of inhaling tobacco smoke.
- The cannabis plant has many naturally occurring substances that are of great interest in science and medicine. Isolated compounds from the cannabis plant include Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not. Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids isolated from the cannabis plant. Many researches confirmed the medicinal value of cannabinoids. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
- The IUPAC nomenclature of THC is (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol. CBD's IUPAC nomenclature is 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-1,3-diol). CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
- Cannabinoids can be isolated by extraction from cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis, and Cannabis indicia. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
- Nabilone (racemic(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name dronabinol ((−)-(6aR,10aR)-6,6,9-trimythel-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol)). These synthetic cannabinoids are sold for food supplement purposes and investigated for medicinal purpose. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.
- In patients suffering from Acquired Immune Deficiency Syndrome (AIDS), lack of appetite, nausea, vomiting, and pain are common related symptoms. THC and other cannabinoids are used to treat these conditions. Similarly, symptoms associated with Parkinson's disease, such as tremors, are also treated with cannabinoids. Various conditions may also be treated or alleviated by the absorption of cannabinoids and derivatives thereof. Conditions that may be treated or alleviated include nausea, vomiting, emesis, pain, lethargy, alcohol induced disorders, multiple sclerosis, inflammatory bowel disorders, arthritis, dermatitis, systemic lupus erythematosus, inflammation, convulsions, psychotic episodes, some cancers, peripheral neuropathic pain, diabetic neuropathy, shingles, burns, actimic keratosis, oral cavity sores and ulcers, seborrheic dermatitis, ankylosing spondylitis, Reiter syndrome, psoriatic arthritis, joint pain, chondrocalcinosis, fibromyalgia, musculoskeletal pain, polymyositis, neuropathic-postoperative complications, acute nonspecific tenosynovitis, epicondylitis, bursitis, post-traumatic osteoarthritis, juvenile rheumatoid arthritis, synovitis, pancreatitis, contact dermatitis, bullous dermatitis herpetiformis, eczema, mycosis fungoides, pemphigus, severe erythema multiforme, seborrehic dermatitis, and seizures. Cannabinoids are further shown to have broad antioxidant and neuroprotective properties along with immunomodulatory effects.
- Cannabis abuse among chronic users is also seen, especially when raw cannabis plant materials are consumed by smoking. Withdrawal symptoms are observed with discontinuance of cannabis use. Collectively, cannabis abuse is referred to as cannabis use disorder. However, some cannabinoids, such as CBD, may be useful in treating cannabis use disorder.
- Delivering cannabinoids through membranes in mammals remains a challenge. This is due to the hydrophobic nature of cannabinoids. Transdermal delivery of cannabinoids faces many challenges, and penetration enhancers are usually required for effective delivery. Pulmonary delivery has many advantages, one of which is the available surface area in the pulmonary airways.
- Cannabidiol from hemp is marketed in the United States as a dietary supplement. Various products containing cannabidiol have been marketed in recent years. Cannabidiol may be consumed by digestion or by transdermal delivery. However, a more effective method to deliver cannabidiol for fast absorption by a mammal, preferably a human being, is still sought.
- Smoking may be necessary in limited circumstances. When a person needs a certain substance to be delivered into his/her body, but the substance is only available in smoke-able form, that person's options may be limited. An example is the use of medical marijuana. Naturally occurring compounds such as cannabidiol can be found in certain parts of the marijuana plants. A person wishing to consume the compounds found in the marijuana plants due to health reasons and under legal conditions may be limited to smoking the plant materials.
- Many people dislike smoking. With the many disadvantages of smoking, it is clear that such dislikes are prevalent and understandable. Some simply dislike smoking due to the stigma associated with the habit. To address this problem, vaporizers are used. While eliminating some of the disadvantages of smoking by a cigarette or pipe, vaporizers are bulky, hard to set up, and inconvenient to use.
- There is a need to have a means to deliver cannabidiol via the pulmonary pathway while ensuring the subject's safety and minimizing risks. Given the benefits of substance delivery via the pulmonary pathway, the disadvantages of smoking, and the available technology of the e-cigarette, this present invention offers a method to deliver cannabidiol via the pulmonary route while minimizing the adverse effects of smoking.
- The present invention relates to a mixture composition of cannabidiol with emulsifiers and/or flavor enhancers to form a composition to be smoked in an electronic cigarette. The present invention also relates to methods to make the smoke-able cannabidiol composition. The present invention finally relates to a smoking device containing a smoke-able cannabidiol composition.
- This present invention is capable of being embodied in various forms. The description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the attached claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
- As used herein, the verb “to comprise” in this description, claims, and other conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
- Reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one.” Additionally, the words “a” and “an” when used in the present document in concert with the words “comprising” or “containing” denote “one or more.”
- The word “cannabinoid” used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs (Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 3-(1,1-dimethylheptyl)-6,6a7,8,10,10a-hexahydro-1-1hydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9-ol,(−)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-1,1-dimethylheptyl, (+)-(3S,4S)-7-hydroxy-Δ-6-tetrahydrocannabinol, and Δ8-tetrahydrocannabinol-11-oic acid); certain piperidine analogs (e.g., (−)-(6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-6-methyl-1-3-[(R)-1-methyl-4-phenylbutoxy]-1,9-phenanthridinediol 1-acetate)); certain aminoalkylindole analogs (e.g., (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylm-ethyl)-pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthelenyl-methanone); certain open pyran-ring analogs (e.g., 2-[3-methyl-6-(1-methylethenyl-2-cyclohexen-1-yl]-5-pentyl-1,3-benzendi-ol, and 4-(1,1-dimethylheptyl)-2,3′-dihydroxy-6′-α-(3-hydroxypropyl)-1′,-2′,3′,4′,5′,6′-hexahydrobiphenyl), their salts, solvates, metabolites, and metabolic precursors.
- The word “smoke-able” used in this description, claims, and other conjugations is used to mean the capability of a composition to be vaporized at room temperature and atmospheric pressure conditions and inhaled by a mammal, preferably a human being.
- The word “cannabidiol” refers to cannabidiol and cannabidiol derivatives. As used in this application, cannabidiol is obtained from industrial hemp extract with trace amount of THC.
- This present invention relates to a composition comprising cannabidiol with emulsifiers and/or flavor enhancers. The resulting composition may be vaporized by the heat applied by an electronic cigarette. A mammal, preferably a human, may inhale this vapor, which contains cannabidiol. Upon inhalation, the mammal may absorb the cannabidiol via pulmonary route.
- In a preferred embodiment, cannabidiol is naturally derived and provided as a part of hemp oil. Hemp oil is derived by cold-pressing of the seeds and mature stalks of the Cannabis sativa L. plant. Cold-pressed oil is then distilled to increase cannabidiol concentration. Impurities may be any cannabinoids that are not cannabidiol, fatty acids such as linoleic acid and α-linoleic acid, which are natural components of hemp oil, β-caryophyllene, myrcene, and β-sitosterol. In this embodiment, cannabidiol may contain impurities in an amount of less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 55%, less than 50%, less than 45%, less than 40%, or less than 35%.
- In another preferred embodiment, cannabidiol may be artificially synthesized and is substantially free from impurities. Synthetic cannabidiol must be combined with at least one emulsifier to form a uniform liquid mixture that may be vaporized.
- According to the present invention, the composition is a mixture of cannabidiol with an emulsifier, preferably polyethylene glycol 400 (PEG-400), but may also be propylene glycol or vegetable glycol. PEG-400 is highly hydrophilic. The combination of cannabidiol in hemp oil and PEG-400 gives in a uniform composition. Moreover, this composition does not separate, ensuring even distribution of cannabidiol in the composition.
- Vegetable glycol gives more smoke when the composition vaporizes during use, while propylene glycol enhances the taste of the composition during vaporization. The weight percentage of propylene glycol or vegetable glycol in the composition is the same as that recommended for the polyethylene glycol-400 concentration.
- In another embodiment, a combination of different emulsifiers may be used. Using a combination of PEG-400 and vegetable glycol gives the composition a smoother feel, produces more smoke with each drag, while guarding against separation when the composition is left unused for extended periods.
- Cannabidiol is the main component to be delivered in this composition. In this composition, cannabidiol concentration is present in a total amount by weight of about 0.1% to about 90%, about 0.1% to about 89%, about 0.1% to about 88%, about 0.1% to about 87%, about 0.1% to about 86%, about 0.1% to about 85%, about 0.1% to about 84%, about 0.1% to about 83%, about 0.1% to about 82%, about 0.1% to about 81%, about 0.1% to about 80%, about 0.1% to about 79%, about 0.1% to about 78%, about 0.1% to about 77%, about 0.1% to about 76%, about 0.1% to about 75%, about 0.1% to about 74%, about 0.1% to about 73%, about 0.1% to about 72%, about 0.1% to about 70.1%, about 0.1% to about 70%, about 0.1% to about 69%, about 0.1% to about 68%, about 0.1% to about 67%, about 0.1% to about 66%, about 0.1% to about 65%, about 0.1% to about 64%, about 0.1% to about 63%, about 0.1% to about 62%, about 0.1% to about 60.1%, about 0.1% to about 60%, about 0.1% to about 59%, about 0.1% to about 58%, about 0.1% to about 57%, about 0.1% to about 56%, about 0.1% to about 55%, about 0.1% to about 54%, about 0.1% to about 53%, about 0.1% to about 52%, about 0.1% to about 50.1%, about 0.1% to about 50%, about 0.1% to about 10%, about 0.1% to about 48%, about 0.1% to about 47%, about 0.1% to about 46%, about 0.1% to about 45%, about 0.1% to about 44%, about 0.1% to about 43%, about 0.1% to about 42%, about 0.1% to about 40.1%, about 0.1% to about 40%, about 0.1% to about 39%, about 0.1% to about 38%, about 0.1% to about 37%, about 0.1% to about 36%, about 0.1% to about 35%, about 0.1% to about 34%, about 0.1% to about 33%, about 0.1% to about 32%, about 0.1% to about 30.1%, about 0.1% to about 30%, about 0.1% to about 29%, about 0.1% to about 28%, about 0.1% to about 27%, about 0.1% to about 26%, about 0.1% to about 25%, about 0.1% to about 24%, about 0.1% to about 23%, about 0.1% to about 22%, about 0.1% to about 20.1%, about 0.1% to about 20%, about 0.1% to about 19%, about 0.1% to about 18%, about 0.1% to about 17%, about 0.1% to about 16%, about 0.1% to about 15%, about 0.1% to about 14%, about 0.1% to about 13%, about 0.1% to about 12%, about 0.1% to about 10.1%, about 0.1% to about 10%, about 0.1% to about 9%, about 0.1% to about 8%, about 0.1% to about 7%, about 0.1% to about 6%, about 0.1% to about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%.
- In another preferred embodiment, cannabidiol may be present in an amount of about 1% to about 5% (wt/wt) of the composition.
- The emulsifier is present in this composition in a total amount by weight of about 10% to about 99.9%, about 10% to about 99%, about 10% to about 98%, about 10% to about 97%, about 10% to about 96%, about 10% to about 95%, about 10% to about 94%, about 10% to about 93%, about 10% to about 92%, about 10% to about 90.1%, about 10% to about 90%, about 10% to about 89%, about 10% to about 88%, about 10% to about 87%, about 10% to about 86%, about 10% to about 85%, about 10% to about 84%, about 10% to about 83%, about 10% to about 82%, about 10% to about 80.1%, about 10% to about 80%, about 10% to about 79%, about 10% to about 78%, about 10% to about 77%, about 10% to about 76%, about 10% to about 75%, about 10% to about 74%, about 10% to about 73%, about 10% to about 72%, about 10% to about 70.1%, about 10% to about 70%, about 10% to about 69%, about 10% to about 68%, about 10% to about 67%, about 10% to about 66%, about 10% to about 65%, about 10% to about 64%, about 10% to about 63%, about 10% to about 62%, about 10% to about 60.1%, about 10% to about 60%, about 10% to about 59%, about 10% to about 58%, about 10% to about 57%, about 10% to about 56%, about 10% to about 55%, about 10% to about 54%, about 10% to about 53%, about 10% to about 52%, about 10% to about 50.1%, about 10% to about 50%, about 10% to about 49%, about 10% to about 48%, about 10% to about 47%, about 10% to about 46%, about 10% to about 45%, about 10% to about 44%, about 10% to about 43%, about 10% to about 42%, about 10% to about 40.1%, about 10% to about 40%, about 10% to about 39%, about 10% to about 38%, about 10% to about 37%, about 10% to about 36%, about 10% to about 35%, about 10% to about 34%, about 10% to about 33%, about 10% to about 32%, about 10% to about 30.1%, about 10% to about 30%, about 10% to about 29%, about 10% to about 28%, about 10% to about 27%, about 10% to about 26%, about 10% to about 25%, about 10% to about 24%, about 10% to about 23%, about 10% to about 22%, about 10% to about 20.1%, about 10% to about 20%, about 10% to about 19%, about 10% to about 18%, about 10% to about 17%, about 10% to about 16%, about 10% to about 15%, about 10% to about 14%, about 10% to about 13%, about 10% to about 12%, about 10% to about 11%.
- When PEG-400 and vegetable glycol are used together, PEG-400 comprises most of the emulsifier mass. Specifically, PEG-400 may be present by weight at between about 40% to about 80%, and vegetable glycol may be present by weight at between about 5% to about 15%. The balance of the composition may be flavor enhancer and cannabidiol.
- The composition may further comprise a flavor enhancer to substantially change the flavor of the smoke. The flavor enhancer is present in this composition in a total amount by weight of about 1% to about 80%, about 1% to about 79%, about 1% to about 78%, about 1% to about 77%, about 1% to about 76%, about 1% to about 75%, about 1% to about 74%, about 1% to about 73%, about 1% to about 72%, about 1% to about 70.1%, about 1% to about 70%, about 1% to about 69%, about 1% to about 68%, about 1% to about 67%, about 1% to about 66%, about 1% to about 65%, about 1% to about 64%, about 1% to about 63%, about 1% to about 62%, about 1% to about 61%, about 1% to about 60%, about 1% to about 59%, about 1% to about 58%, about 1% to about 57%, about 1% to about 56%, about 1% to about 55%, about 1% to about 54%, about 1% to about 53%, about 1% to about 52%, about 1% to about 51%, about 1% to about 50%, about 1% to about 10%, about 1% to about 48%, about 1% to about 47%, about 1% to about 46%, about 1% to about 45%, about 1% to about 44%, about 1% to about 43%, about 1% to about 42%, about 1% to about 41%, about 1% to about 40%, about 1% to about 39%, about 1% to about 38%, about 1% to about 37%, about 1% to about 36%, about 1% to about 35%, about 1% to about 34%, about 1% to about 33%, about 1% to about 32%, about 1% to about 31%, about 1% to about 30%, about 1% to about 29%, about 1% to about 28%, about 1% to about 27%, about 1% to about 26%, about 1% to about 25%, about 1% to about 24%, about 1% to about 23%, about 1% to about 22%, about 1% to about 21%, about 1% to about 20%, about 1% to about 19%, about 1% to about 18%, about 1% to about 17%, about 1% to about 16%, about 1% to about 15%, about 1% to about 14%, about 1% to about 13%, about 1% to about 12%, about 1% to about 11%, about 1% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%.
- In a preferred embodiment, the flavor enhancer is present in the amount by weight of about 20% to about 40% of the composition. In yet another preferred embodiment, the flavor enhancer is present in the amount by weight of about 40% to about 60% of the composition. In another embodiment, different kinds of flavor enhancer may be mixed in, such that the smoke-able composition may have multiple flavors.
- In another preferred embodiment, cannabidiol may be mixed with a flavor enhancer and without an emulsifier. Trace amount of water and other impurities may be present. In this embodiment, cannabidiol may be supplied in less pure form, wherein the cannabidiol is in oil form with other cannabinoids and other components of hemp oil, such as linoleic acid, α-linoleic acid, β-caryophyllene, myrcene, and β-sitosterol. THC may be present in trace amounts. Impurities may be present in the amount of less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 35%, less than 20%, less than 15%, less than 10%, less than 5%, or less than 1%.
- Cannabidiol and a flavor enhancer may be obtained in a desired quantity. The two components are placed in a container and mixed using a propeller, a magnetic stirrer or a shaking mechanism. Magnetic stirrer is the best mixing method, as it prevents minor bubbles from forming in the mixture and affecting the smoking experience. After mixing, the composition may be used for smoking.
- In this embodiment, cannabidiol is present in a total amount by weight of about 70% to about 95%, about 70% to about 94%, about 70% to about 93%, about 70% to about 92%, about 70% to about 91%, about 70% to about 90%, about 70% to about 89%, about 70% to about 88%, about 70% to about 87%, about 70% to about 86%, about 70% to about 85%, about 70% to about 84%, about 70% to about 83%, about 70% to about 82%, about 70% to about 80.1%, about 70% to about 80%, about 70% to about 79%, about 70% to about 78%, about 70% to about 77%, about 70% to about 76%, about 70% to about 75%, about 70% to about 74%, about 70% to about 73%, about 70% to about 72%, about 70% to about 71%.
- A flavor enhancer is present in a total amount by weight of about 5% to about 50%, 5% to about 49%, 5% to about 48%, 5% to about 47%, 5% to about 46%, 5% to about 45%, 5% to about 44%, 5% to about 43%, 5% to about 42%, 5% to about 41%, 5% to about 40%, 5% to about 39%, 5% to about 38%, 5% to about 37%, 5% to about 36%, 5% to about 35%, 5% to about 34%, 5% to about 33%, 5% to about 32%, 5% to about 31%, 5% to about 30%, about 5% to about 29%, about 5% to about 28%, about 5% to about 27%, about 5% to about 26%, about 5% to about 25%, about 5% to about 24%, about 5% to about 23%, about 5% to about 22%, about 5% to about 20.1%, about 5% to about 20%, about 5% to about 19%, about 5% to about 18%, about 5% to about 17%, about 5% to about 16%, about 5% to about 15%, about 5% to about 14%, about 5% to about 13%, about 5% to about 12%, about 5% to about 10.1%, about 5% to about 10%, about 5% to about 9%, about 5% to about 8%, about 5% to about 7%, about 5% to about 6%.
- Polyethylene glycol-400, propylene glycol, and vegetable glycol are widely available from industrial sellers and the marketplace. PEG-400 is the most effective emulsifiers, as they have strong hydrophilic capability, even though propylene glycol and vegetable glycol are also effective.
- Cannabidiol is available as an isolated extraction from the cannabis plant, namely from industrial hemp, and may be obtained on the legal market. Cannabidiol may also be obtained from synthetic sources. However, synthetic cannabidiol should only be used under strict legal requirements where legally appropriate. The synthesis of cannabidiol can be found in Navak & Salemink, TetradedronLett. 23, 253 (1982). This publication is included herein as references.
- Flavor enhancers may be chosen from the list comprising of apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any other flavor. Flavor enhancers are available for purchase commercially. Most flavor enhancers are available in oil form and mix well with cannabidiol and emulsifiers.
- Polyethylene glycol-400 (or vegetable glycol, or propylene glycol) may be combined with cannabidiol and a flavor enhancer. The resulting mixture is stirred or mixed well, either by a propeller, a magnetic stirrer, or by a shaking mechanism.
- In a preferred embodiment, PEG-400 is used at a concentration of about 90% (wt/wt). Cannabidiol derived from hemp oil is present at a concentration of about 5% (wt/wt). A flavor enhancer, such as mint, is present at a concentration of about 5% (wt/wt). Trace amounts of water may be found in this composition. Cannabidiol in hemp oil dissolves well in PEG-400 and the mixture vaporizes well during smoking by an e-cigarette.
- The use of polyethylene glycol-400, propylene glycol, or vegetable glycol in combination with cannabidiol gives a smoke-able e-cigarette liquid. Flavor enhancers may be added into the mixture as needed. The weight percentages for flavor enhancers are given above.
- Trace amount of water and other cannabinoids may be present in this composition, as the cannabidiol purification process may leave trace amounts of water and other cannabinoids. It is to be understood that cannabidiol may contain certain impurities.
- The smoke-able cannabidiol composition may be smoked using an e-cigarette. The composition may be injected into an e-cigarette cartridge. The e-cigarette cartridge containing the smoke-able composition may be placed into an e-cigarette housing and be ready for smoking. The e-cigarette may be charged before the smoking of the smoke-able cannabidiol composition. Upon inhalation of the smoke from the smoke-able cannabidiol composition, cannabidiol is delivered into the pulmonary pathway and absorbed by the smoker.
- In the following examples, cannabidiol is provided as part of hemp oil. Hemp oil in the following examples contains 10% (wt/wt) of cannabidiol. Hence, 1 grams of hemp oil contains 0.1 gram of cannabidiol.
- Cannabidiol e-cigarette liquid composition with PEG-400
-
Weight Unit % w/w PEG-400 90 g 90 CBD (in hemp oil) 1 g 1 Mint oil 9 g 9 Total 100 100 - All ingredients at the quantity above are obtained. Weigh 90 grams of polyethylene glycol-400 into a container. Use a pipette to transfer ingredients at lower percentage weight, such as CBD in hemp oil and mint oil, into a container. Weigh 1 grams of CBD and 9 grams of mint flavor; then mix both CBD in hemp oil and mint flavor into the container of polyethylene glycol-400. Mix well before use. A magnetic stirrer stifling for 6 hours ensures dispersion of this composition.
- Cannabidiol e-cigarette liquid composition with vegetable glycol
-
Weight Unit % w/w Vegetable glycol 80 g 80 CBD (in hemp oil) 14 g 14 Orange oil 6 g 6 Total 100 100 - All ingredients at the quantity above are obtained. Weigh 80 grams of vegetable glycol into a container. Use a pipette to transfer ingredients at lower percentage weight, such as CBD and orange oil, into a container. Weigh 14 grams of CBD in hemp oil and 6 grams of orange oil; then mix both the CBD in hemp oil the orange oil into the container of vegetable glycol. Mix well before use. A magnetic stirrer stirring for 6 hours ensures dispersion of this composition.
- Cannabidiol e-cigarette liquid composition with PEG-400 and strawberry flavor
-
Weight Unit % w/w PEG-400 69 g 69 CBD (in hemp oil) 1 g 1 Strawberry flavor 30 g 30 Total 100 100 - All ingredients at the quantity above are obtained. Weigh 69 grams of PEG-400 into a container. Use a pipette to transfer CBD in hemp oil into a container. Weigh 1 grams of CBD, then mix the CBD in hemp oil into the container of PEG-400. Add 30 grams of strawberry flavor into the container. Mix well before use. A magnetic stirrer stirring for 5 hours ensures dispersion of this composition.
- All references, including publications, patent applications, and patents cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- It will be readily apparent to those skilled in the art that a number of modifications and changes may be made without departing from the spirit and the scope of the present invention. It is to be understood that any ranges, ratios, and range of ratios that can be derived from any of the data disclosed herein represent further embodiments of the present disclosure and are included as part of the disclosure as though they were explicitly set forth. This includes ranges that can be formed that do or do not include a finite upper and/or lower boundary. Accordingly, a person of ordinary skill in the art will appreciate that such values are unambiguously derivative from the data presented herein.
Claims (25)
1. A smoke-able composition comprising:
cannabidiol in the amount of about 0.1% to about 90% (wt/wt) of the composition; and
at least one emulsifier in the amount of about 10% to about 99.9% (wt/wt) of the composition.
2. The composition of claim 1 , wherein cannabidiol is present in an amount of about 0.1% to about 1% (wt/wt) of the composition.
3. The composition of claim 1 , wherein cannabidiol is present in an amount of about 1% to about 5% (wt/wt) of the composition.
4. The composition of claim 1 , wherein cannabidiol is synthetic.
5. The composition of claim 1 , wherein cannabidiol is derived from natural sources.
6. The composition of claim 1 , wherein cannabidiol is derived from hemp oil.
7. The composition of claim 1 , wherein the emulsifier is polyethylene glycol-400.
8. The composition of claim 1 , wherein the emulsifier is propylene glycol.
9. The composition of claim 1 , wherein the emulsifier is vegetable glycol.
10. The composition of claim 1 , wherein two emulsifiers are used.
11. The composition of claim 10 , where in two emulsifiers are chosen from a list comprising of polyethylene glycol-400, propylene glycol, and vegetable glycol.
12. The composition of claim 1 , further comprising a flavor enhancer.
13. The composition of claim 12 , wherein the flavor enhancer is selected from a flavor enhancer group consisting of apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, dates, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, terpene, and honey.
14. The composition of claim 13 , wherein the flavor enhancer is in the amount of about 1% to about 80% (wt/wt) of the composition.
15. The composition of claim 13 , wherein the flavor enhancer is in the amount of about 20% to about 40% (wt/wt) of the composition.
16. The composition of claim 13 , wherein the flavor enhancer is in the amount of about 40% to about 60% (wt/wt) of the composition.
17. A method to make a smoke-able composition comprising the steps of:
placing a quantity of at least one emulsifier in a container;
adding a quantity of cannabidiol; and
mixing the composition using a propeller, a magnetic stirrer, or a shaking mechanism.
18. The method of claim 17 , wherein the quantity of emulsifier comprises about 10% to about 99.9% (wt/wt) of the composition.
19. The method of claim 17 , wherein the quantity of cannabidiol comprises about 0.1% to about 90% (wt/wt) of the composition
20. The method of claim 17 , further comprising the step of adding a quantity of flavor enhancer.
21. The method of claim 17 , wherein the quantity of flavor enhancer comprises about 1% to about 80% (wt/wt) of the composition.
22. A method for pulmonarily administering a cannabidiol composition to a mammal comprising the steps of:
(a) providing a smoke-able composition comprising:
(i) cannabidiol in the amount of about 0.1% to about 90% (wt/wt) of the composition; and
(ii) at least one emulsifier in an amount of about 10% to about 99.9% (wt/wt) of the composition;
(b) placing the smoke-able composition in an appropriate quantity in an electronic cigarette cartridge;
(c) placing the e-cigarette cartridge containing the smoke-able composition into an electronic cigarette housing; and
(c) the mammal smokes the smoke-able composition using the electronic cigarette.
23. The method of claim 23 , wherein the smoke-able composition further comprises a flavor enhancer in an amount of about 1% to about 80% (wt/wt) of the composition.
24. The method of claim 23 , wherein the flavor enhancer is chosen from a list consisting of apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, dates, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, terpene, and honey.
25. A system for pulmonarily administering of a cannabidiol composition to a mammal, comprising:
(a) a cartridge for storing a smoke-able cannabidiol composition according to any one of claims 1 -16;
(b) an electronic cigarette wherein the cartridge is housed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/528,051 US20150181924A1 (en) | 2013-10-31 | 2014-10-30 | Cannabidiol liquid composition for smoking |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898273P | 2013-10-31 | 2013-10-31 | |
| US14/528,051 US20150181924A1 (en) | 2013-10-31 | 2014-10-30 | Cannabidiol liquid composition for smoking |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20150181924A1 true US20150181924A1 (en) | 2015-07-02 |
Family
ID=53480363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/528,051 Abandoned US20150181924A1 (en) | 2013-10-31 | 2014-10-30 | Cannabidiol liquid composition for smoking |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20150181924A1 (en) |
Cited By (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140209109A1 (en) * | 2013-01-30 | 2014-07-31 | Raymond Louis Larson | Smokeless THC and Administration Method Thereof |
| CN105124737A (en) * | 2015-09-02 | 2015-12-09 | 云南中烟工业有限责任公司 | Method of promoting moisturizing and aroma enhancement effects of cigarettes by means of Damask roses |
| US20150359756A1 (en) * | 2014-06-17 | 2015-12-17 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| CN105167169A (en) * | 2015-08-06 | 2015-12-23 | 云南中烟工业有限责任公司 | Fruit-flavored composite E-cigarette tobacco tar |
| CN105768198A (en) * | 2016-04-29 | 2016-07-20 | 江苏中烟工业有限责任公司 | Electronic cigarette juice with moss faint scent feature and preparation method thereof |
| US9522123B2 (en) | 2009-07-03 | 2016-12-20 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
| US9770055B2 (en) | 2015-05-15 | 2017-09-26 | Lunatech, Llc | Vaporizable material handling for electronic vapor device |
| US9888725B2 (en) | 2015-07-28 | 2018-02-13 | Lunatech, Llc | Inhalation puff counter gauge and display system |
| US9888723B2 (en) | 2015-05-15 | 2018-02-13 | Lunatech, Llc | Hybrid vapor delivery system utilizing nebulized and non-nebulized elements |
| US9933790B2 (en) | 2015-06-15 | 2018-04-03 | Lunatech, Llc | Peer-to-peer air analysis and treatment |
| US9936737B2 (en) | 2015-10-28 | 2018-04-10 | Lunatech, Llc | Methods and systems for a dual function vapor device |
| CN108186566A (en) * | 2018-01-24 | 2018-06-22 | 云南汉木森生物科技有限责任公司 | A kind of nervous, relieving mental strain and helping sleep Alevaire and preparation method thereof of releiving |
| US10039320B2 (en) | 2015-05-14 | 2018-08-07 | Lunatech, Llc | Multi-chambered vaporizer and blend control |
| US10042369B2 (en) | 2015-06-16 | 2018-08-07 | Lunatech, Llc | Vapor device for filtering and testing material |
| US10060639B2 (en) | 2015-06-11 | 2018-08-28 | Lunatech, Llc | Air analyzer and treatment apparatus |
| US10065138B2 (en) | 2015-06-17 | 2018-09-04 | Lunatech, Llc | Remote controllable air treatment apparatus |
| US10088463B2 (en) | 2015-06-11 | 2018-10-02 | Lunatech, Llc | Calibrating electronic vapor device |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US20180289062A1 (en) * | 2017-03-30 | 2018-10-11 | Markham Biotech Inc. | Cannabinoid Formulations for Aerosol Devices and Methods Thereof |
| CN108685159A (en) * | 2017-04-07 | 2018-10-23 | 宝涵 | A kind of rose scent electronic cigarette tobacco tar |
| CN108713790A (en) * | 2018-04-13 | 2018-10-30 | 孙永德 | Replace traditional tobacco leaf Chinese herbal medicine cigarette preparation method with lotus leaf |
| US10215430B2 (en) | 2015-06-15 | 2019-02-26 | Lunatech, Llc | Electronic vapor and analysis with HVAC integration |
| US10215429B2 (en) | 2015-06-15 | 2019-02-26 | Lunatech, Llc | Localized air sensing and treatment |
| CN109393546A (en) * | 2017-08-16 | 2019-03-01 | 王学彬 | A kind of electronic cigarette liquid and preparation method thereof comprising jasmine essential oil |
| CN109452684A (en) * | 2019-01-03 | 2019-03-12 | 四川中烟工业有限责任公司 | A kind of electronic cigarette liquid and preparation method thereof with pineapple flavor fragrance |
| CN109875105A (en) * | 2019-03-20 | 2019-06-14 | 福建绿色黄金生物科技有限公司 | Composition, preparation method and applications |
| CN109984374A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Citrus extracts solution, citrus electronics tobacco tar and preparation method thereof |
| CN109984372A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Mango extract solution, mango electronics tobacco tar and preparation method thereof |
| CN109984373A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Pear extract solution, pear electronics tobacco tar and preparation method thereof |
| US10376586B2 (en) * | 2016-02-16 | 2019-08-13 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| CN110115397A (en) * | 2019-04-30 | 2019-08-13 | 安徽中烟工业有限责任公司 | A kind of induction-heatable material for magnetic grain soaking |
| CN110200311A (en) * | 2019-03-20 | 2019-09-06 | 福建绿色黄金生物科技有限公司 | It is a kind of for the oolong tea of electronic cigarette and the composition of lemon and its application |
| CN110200310A (en) * | 2019-03-20 | 2019-09-06 | 福建绿色黄金生物科技有限公司 | It is a kind of for the oolong tea of electronic cigarette and the composition of lemon and its application |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| EP3676238A1 (en) * | 2017-09-01 | 2020-07-08 | Pureform Global, Inc. | Synthetic cannabidiol compositions and methods of making the same |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| JP2020110045A (en) * | 2019-01-08 | 2020-07-27 | ワンインチ合同会社 | Liquid composition for electronic cigarette and electronic cigarette including the same |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| CN111543671A (en) * | 2020-05-07 | 2020-08-18 | 南京中医药大学 | An electronic cigarette oil for aerosol device and its preparation method and application |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10799467B2 (en) | 2010-03-30 | 2020-10-13 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| CN112007080A (en) * | 2020-09-14 | 2020-12-01 | 云南汉木森生物科技有限责任公司 | Aerosol for relieving, helping sleep and resisting depression and preparation method thereof |
| WO2020244116A1 (en) * | 2019-06-04 | 2020-12-10 | 云南喜科科技有限公司 | Multi-section heat-not-burn product containing hemp component and preparation method therefor |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| WO2021069908A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| WO2021069909A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| WO2021069907A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| WO2021255251A1 (en) * | 2020-06-19 | 2021-12-23 | Cannovex Bv | Pulmonary formulation comprising cannabinoids |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| FR3113563A1 (en) * | 2020-09-03 | 2022-03-04 | Cids France | Use of plant phytocannabinoids extracted by distillation method for the manufacture of e-liquids |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| EP3984522A1 (en) * | 2020-10-19 | 2022-04-20 | Shima Khaki | Composition, device and use |
| WO2022077219A1 (en) * | 2020-10-13 | 2022-04-21 | 深圳市舜宝科技有限公司 | Composition, preparation method, and tea cartridge |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US20220152323A1 (en) * | 2020-11-13 | 2022-05-19 | Aari Ruben | Medical therapy using cigarettes |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US20220304943A1 (en) * | 2019-10-28 | 2022-09-29 | Canopy Growth Corporation | Flowable cannabinoid compositions having high effective concentrations |
| CN115725366A (en) * | 2022-11-09 | 2023-03-03 | 河北中烟工业有限责任公司 | Lotus-flavored essence for cigarettes and cigarettes |
| IT202100029582A1 (en) * | 2021-11-23 | 2023-05-23 | Ansce Bio Generic Srl | Blend based on hemp seed oil, vitamin E, vitamin A and beta-caryophyllene with antioxidant and anti-inflammatory action |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
-
2014
- 2014-10-30 US US14/528,051 patent/US20150181924A1/en not_active Abandoned
Cited By (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9522123B2 (en) | 2009-07-03 | 2016-12-20 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
| US12023305B2 (en) | 2010-03-30 | 2024-07-02 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| US10799467B2 (en) | 2010-03-30 | 2020-10-13 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10639439B2 (en) * | 2013-01-30 | 2020-05-05 | Midwest Pharmaceuticals, Llc | Smokeless THC and administration method thereof |
| US20140209109A1 (en) * | 2013-01-30 | 2014-07-31 | Raymond Louis Larson | Smokeless THC and Administration Method Thereof |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US9949937B2 (en) | 2014-06-17 | 2018-04-24 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11311498B2 (en) * | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US9956183B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US9956184B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US9956186B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US9956185B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US9949936B2 (en) | 2014-06-17 | 2018-04-24 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US20150359756A1 (en) * | 2014-06-17 | 2015-12-17 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
| US11793770B2 (en) | 2014-06-27 | 2023-10-24 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
| US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US12427160B2 (en) | 2014-10-14 | 2025-09-30 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US12318356B2 (en) | 2014-10-14 | 2025-06-03 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10039320B2 (en) | 2015-05-14 | 2018-08-07 | Lunatech, Llc | Multi-chambered vaporizer and blend control |
| US9770055B2 (en) | 2015-05-15 | 2017-09-26 | Lunatech, Llc | Vaporizable material handling for electronic vapor device |
| US9888723B2 (en) | 2015-05-15 | 2018-02-13 | Lunatech, Llc | Hybrid vapor delivery system utilizing nebulized and non-nebulized elements |
| US10060639B2 (en) | 2015-06-11 | 2018-08-28 | Lunatech, Llc | Air analyzer and treatment apparatus |
| US10088463B2 (en) | 2015-06-11 | 2018-10-02 | Lunatech, Llc | Calibrating electronic vapor device |
| US10215429B2 (en) | 2015-06-15 | 2019-02-26 | Lunatech, Llc | Localized air sensing and treatment |
| US9933790B2 (en) | 2015-06-15 | 2018-04-03 | Lunatech, Llc | Peer-to-peer air analysis and treatment |
| US10215430B2 (en) | 2015-06-15 | 2019-02-26 | Lunatech, Llc | Electronic vapor and analysis with HVAC integration |
| US10042369B2 (en) | 2015-06-16 | 2018-08-07 | Lunatech, Llc | Vapor device for filtering and testing material |
| US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10065138B2 (en) | 2015-06-17 | 2018-09-04 | Lunatech, Llc | Remote controllable air treatment apparatus |
| US9888725B2 (en) | 2015-07-28 | 2018-02-13 | Lunatech, Llc | Inhalation puff counter gauge and display system |
| CN105167169A (en) * | 2015-08-06 | 2015-12-23 | 云南中烟工业有限责任公司 | Fruit-flavored composite E-cigarette tobacco tar |
| US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| CN105124737A (en) * | 2015-09-02 | 2015-12-09 | 云南中烟工业有限责任公司 | Method of promoting moisturizing and aroma enhancement effects of cigarettes by means of Damask roses |
| US9936737B2 (en) | 2015-10-28 | 2018-04-10 | Lunatech, Llc | Methods and systems for a dual function vapor device |
| US10561731B2 (en) | 2016-02-16 | 2020-02-18 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| US10376586B2 (en) * | 2016-02-16 | 2019-08-13 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| CN105768198A (en) * | 2016-04-29 | 2016-07-20 | 江苏中烟工业有限责任公司 | Electronic cigarette juice with moss faint scent feature and preparation method thereof |
| US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US12213985B2 (en) | 2016-07-01 | 2025-02-04 | Jazz Pharmaceuticals Research Uk Limited | Oral cannabinoid formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US10932497B2 (en) * | 2017-03-30 | 2021-03-02 | Markham Biotech Inc. | Cannabinoid formulations for aerosol devices and methods thereof |
| US20180289062A1 (en) * | 2017-03-30 | 2018-10-11 | Markham Biotech Inc. | Cannabinoid Formulations for Aerosol Devices and Methods Thereof |
| US11659857B2 (en) * | 2017-03-30 | 2023-05-30 | Markham Biotech, Inc. | Cannabinoid formulations for aerosol devices and methods thereof |
| US20210337856A1 (en) * | 2017-03-30 | 2021-11-04 | Markham Biotech Inc. | Cannabinoid Formulations for Aerosol Devices and Methods Thereof |
| CN108685159A (en) * | 2017-04-07 | 2018-10-23 | 宝涵 | A kind of rose scent electronic cigarette tobacco tar |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| CN109393546A (en) * | 2017-08-16 | 2019-03-01 | 王学彬 | A kind of electronic cigarette liquid and preparation method thereof comprising jasmine essential oil |
| EP3676238A1 (en) * | 2017-09-01 | 2020-07-08 | Pureform Global, Inc. | Synthetic cannabidiol compositions and methods of making the same |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| CN108186566A (en) * | 2018-01-24 | 2018-06-22 | 云南汉木森生物科技有限责任公司 | A kind of nervous, relieving mental strain and helping sleep Alevaire and preparation method thereof of releiving |
| CN108713790A (en) * | 2018-04-13 | 2018-10-30 | 孙永德 | Replace traditional tobacco leaf Chinese herbal medicine cigarette preparation method with lotus leaf |
| US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
| CN109452684A (en) * | 2019-01-03 | 2019-03-12 | 四川中烟工业有限责任公司 | A kind of electronic cigarette liquid and preparation method thereof with pineapple flavor fragrance |
| JP7303969B2 (en) | 2019-01-08 | 2023-07-06 | 株式会社ワンインチ | Liquid composition for electronic cigarette and electronic cigarette having the same |
| JP2020110045A (en) * | 2019-01-08 | 2020-07-27 | ワンインチ合同会社 | Liquid composition for electronic cigarette and electronic cigarette including the same |
| CN110200310A (en) * | 2019-03-20 | 2019-09-06 | 福建绿色黄金生物科技有限公司 | It is a kind of for the oolong tea of electronic cigarette and the composition of lemon and its application |
| CN110200311A (en) * | 2019-03-20 | 2019-09-06 | 福建绿色黄金生物科技有限公司 | It is a kind of for the oolong tea of electronic cigarette and the composition of lemon and its application |
| CN109875105A (en) * | 2019-03-20 | 2019-06-14 | 福建绿色黄金生物科技有限公司 | Composition, preparation method and applications |
| CN110115397A (en) * | 2019-04-30 | 2019-08-13 | 安徽中烟工业有限责任公司 | A kind of induction-heatable material for magnetic grain soaking |
| CN109984374A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Citrus extracts solution, citrus electronics tobacco tar and preparation method thereof |
| CN109984372A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Mango extract solution, mango electronics tobacco tar and preparation method thereof |
| CN109984373A (en) * | 2019-05-16 | 2019-07-09 | 铂德(深圳)科技有限公司 | Pear extract solution, pear electronics tobacco tar and preparation method thereof |
| WO2020244116A1 (en) * | 2019-06-04 | 2020-12-10 | 云南喜科科技有限公司 | Multi-section heat-not-burn product containing hemp component and preparation method therefor |
| WO2021069908A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| WO2021069909A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| AU2020364112B2 (en) * | 2019-10-09 | 2023-08-03 | Nicoventures Trading Limited | Aerosolisable material |
| US12439951B2 (en) | 2019-10-09 | 2025-10-14 | Nicoventures Trading Limited | Aerosolizable material with cannabinoid and carrier constituent |
| AU2020365097B2 (en) * | 2019-10-09 | 2023-08-03 | Nicoventures Trading Limited | Aerosolisable material |
| WO2021069907A1 (en) * | 2019-10-09 | 2021-04-15 | Nicoventures Trading Limited | Aerosolisable material |
| AU2020361648B2 (en) * | 2019-10-09 | 2024-03-14 | Nicoventures Trading Limited | Aerosolisable material |
| US20240114949A1 (en) * | 2019-10-09 | 2024-04-11 | Nicoventures Trading Limited | Aerosolizable material |
| US20240122227A1 (en) * | 2019-10-09 | 2024-04-18 | Nicoventures Trading Limited | Aerosolizable material |
| US20220304943A1 (en) * | 2019-10-28 | 2022-09-29 | Canopy Growth Corporation | Flowable cannabinoid compositions having high effective concentrations |
| US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12102619B2 (en) | 2020-02-27 | 2024-10-01 | Jazz Pharmaceuticals Research Uk Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN111543671A (en) * | 2020-05-07 | 2020-08-18 | 南京中医药大学 | An electronic cigarette oil for aerosol device and its preparation method and application |
| WO2021255251A1 (en) * | 2020-06-19 | 2021-12-23 | Cannovex Bv | Pulmonary formulation comprising cannabinoids |
| FR3113563A1 (en) * | 2020-09-03 | 2022-03-04 | Cids France | Use of plant phytocannabinoids extracted by distillation method for the manufacture of e-liquids |
| CN112007080A (en) * | 2020-09-14 | 2020-12-01 | 云南汉木森生物科技有限责任公司 | Aerosol for relieving, helping sleep and resisting depression and preparation method thereof |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| WO2022077219A1 (en) * | 2020-10-13 | 2022-04-21 | 深圳市舜宝科技有限公司 | Composition, preparation method, and tea cartridge |
| EP3984522A1 (en) * | 2020-10-19 | 2022-04-20 | Shima Khaki | Composition, device and use |
| US20220152323A1 (en) * | 2020-11-13 | 2022-05-19 | Aari Ruben | Medical therapy using cigarettes |
| US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| IT202100029582A1 (en) * | 2021-11-23 | 2023-05-23 | Ansce Bio Generic Srl | Blend based on hemp seed oil, vitamin E, vitamin A and beta-caryophyllene with antioxidant and anti-inflammatory action |
| CN115725366A (en) * | 2022-11-09 | 2023-03-03 | 河北中烟工业有限责任公司 | Lotus-flavored essence for cigarettes and cigarettes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150181924A1 (en) | Cannabidiol liquid composition for smoking | |
| US20200197639A1 (en) | Smokeless THC and Administration Method Thereof | |
| EP2170280B1 (en) | An inhalable composition comprising nicotine | |
| US9526270B2 (en) | Synthetic or imitation nicotine compositions, processes and methods of manufacture | |
| EP3558278B1 (en) | Liquid cannabinoid composition | |
| WO2021003467A1 (en) | Metered dosing compositions and methods of use of psychedelic compounds | |
| EP2941135B1 (en) | Tobacco substitute | |
| US11801219B2 (en) | Pouch product suitable for application in an oral cavity | |
| US20150083146A1 (en) | Personal vaporizer liquid for emulsifying oil-soluble compounds and resins | |
| US20220031845A1 (en) | Diluents for compositions of cannabinoids and uses thereof | |
| JP2023120433A (en) | Aerosolized formulation | |
| Eaton et al. | Toxicology of E-cigarette constituents | |
| JP7303969B2 (en) | Liquid composition for electronic cigarette and electronic cigarette having the same | |
| KR20190097038A (en) | Cariophyllene Compositions, Devices, and Methods | |
| US20220062170A1 (en) | Inhalable dosage form of cannabinoid extract | |
| Johnson et al. | Chemosensory contributions of e-cigarette additives on nicotine use | |
| JP7578936B2 (en) | Liquid composition for electronic cigarettes and electronic cigarettes having the same | |
| WO2015067773A1 (en) | Ethanol-based plant macerate | |
| WO2024108295A1 (en) | Cannabichromene-type cannabinoid compositions, methods and uses thereof | |
| Del Ciampo et al. | Adolescents, e-cigarettes and nicotine: a dangerous interaction | |
| Spooner | Cannabis Vaping–What Teens, Their Parents and Their Naturopathic Doctors Need to Know | |
| US20250344763A1 (en) | Other Than Cannabinoids, Flavonoids, and Terpenes | |
| Douglass et al. | Cannabis Extract Formulations and Devices | |
| WO2025019617A1 (en) | Compositions comprising banisteriopsis caapi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HDDC HOLDINGS, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LLAMAS, MICHAEL R.;REEL/FRAME:042860/0124 Effective date: 20140402 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |